ChemoCentryx, Inc. · Mountain View, CA United States (NASDAQ: CCXI)
| 850 Maude Ave. | Phone: 650-210-2900 |
| Mountain View, CA | Fax: 650-210-2910 |
| 94043 | |
| United States | 
Map This Company |
ChemoCentryx, Inc. Rankings
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
The nucleus of ChemoCentryx's research is molecular cell secretions. The drug developer focuses on orally administered drugs targeting the body's chemokine system, a molecular network that regulates inflammatory and immune responses. Its lead candidate in clinical development is Traficet-EN, a potential treatment for Crohn's disease. ChemoCentryx is researching other compounds that could treat type 2 diabetes and a form of brain cancer. Its R&D activities for Traficet-EN are being done in collaboration with
ChemoCentryx, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: CCXI Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 64 |
Executives
11 executives listed for ChemoCentryx, Inc.'s Mountain View, CA location.
| President, CEO, and Director | Thomas Schall | |
|---|---|---|
| SVP Finance, CFO, and Secretary | Susan Kanaya | |
| SVP Drug Discovery and Chief Scientific Officer | Juan Jaen |